PL3122775T3 - Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu - Google Patents

Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu

Info

Publication number
PL3122775T3
PL3122775T3 PL15712629T PL15712629T PL3122775T3 PL 3122775 T3 PL3122775 T3 PL 3122775T3 PL 15712629 T PL15712629 T PL 15712629T PL 15712629 T PL15712629 T PL 15712629T PL 3122775 T3 PL3122775 T3 PL 3122775T3
Authority
PL
Poland
Prior art keywords
gdf
cachexia
cancer
treatment
difference
Prior art date
Application number
PL15712629T
Other languages
English (en)
Inventor
Jörg WISCHHUSEN
Markus JUNKER
Tina SCHÄFER
Dirk PÜHRINGER
Original Assignee
Julius-Maximilians-Universität Würzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1405477.9A external-priority patent/GB2524553C/en
Priority claimed from GB1405475.3A external-priority patent/GB2524552B/en
Application filed by Julius-Maximilians-Universität Würzburg filed Critical Julius-Maximilians-Universität Würzburg
Publication of PL3122775T3 publication Critical patent/PL3122775T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Cosmetics (AREA)
PL15712629T 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu PL3122775T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1405477.9A GB2524553C (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB1405475.3A GB2524552B (en) 2014-03-26 2014-03-26 Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
EP15712629.3A EP3122775B1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer
PCT/EP2015/056654 WO2015144855A1 (en) 2014-03-26 2015-03-26 Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer

Publications (1)

Publication Number Publication Date
PL3122775T3 true PL3122775T3 (pl) 2020-05-18

Family

ID=52745885

Family Applications (2)

Application Number Title Priority Date Filing Date
PL19205321.3T PL3653644T3 (pl) 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów
PL15712629T PL3122775T3 (pl) 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL19205321.3T PL3653644T3 (pl) 2014-03-26 2015-03-26 Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworów

Country Status (22)

Country Link
US (6) US20170204174A1 (pl)
EP (3) EP3122775B1 (pl)
JP (3) JP6865585B2 (pl)
KR (1) KR102520978B1 (pl)
CN (1) CN106536553B (pl)
AU (2) AU2015238264B2 (pl)
BR (1) BR122023027559A2 (pl)
CY (1) CY1122456T1 (pl)
DK (2) DK3653644T5 (pl)
ES (2) ES2965626T3 (pl)
FI (1) FI3653644T3 (pl)
HR (2) HRP20231514T1 (pl)
HU (2) HUE047398T2 (pl)
IL (2) IL248038B (pl)
LT (2) LT3653644T (pl)
NZ (1) NZ724649A (pl)
PL (2) PL3653644T3 (pl)
PT (2) PT3653644T (pl)
RS (1) RS59700B1 (pl)
SI (1) SI3122775T1 (pl)
SM (1) SMT202000064T1 (pl)
WO (1) WO2015144855A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122023027559A2 (pt) 2014-03-26 2024-01-30 Julius-Maximilians-Universität Würzburg Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos
PL3197493T3 (pl) 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
GB201517528D0 (en) * 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
CA3000290C (en) * 2015-10-02 2023-02-21 Julius-Maximilians-Universitat Wurzburg Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers
HRP20221530T1 (hr) * 2015-10-02 2023-03-17 Julius-Maximilians-Universität Würzburg Kombinirana terapija uporabom inhibitora ljudskog rasta i faktora diferencijacije 15 (gdf-15) te blokatora imunološke kontrolne točke
CN109071647B (zh) * 2016-04-27 2022-11-22 诺华股份有限公司 抗生长分化因子15的抗体及其用途
AU2017293450B2 (en) * 2016-07-06 2024-08-08 National Research Council Of Canada Humanized antibodies transmigrating the blood-brain barrier and uses thereof
CA3038846A1 (en) * 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
US20200069774A1 (en) * 2016-12-06 2020-03-05 St Vincent's Hospital Sydney Limited Treatment of obesity and eating disorders
TWI803682B (zh) * 2018-08-20 2023-06-01 美商輝瑞股份有限公司 抗－ｇｄｆ１５抗體、組成物及使用方法
IL302646A (en) * 2020-11-10 2023-07-01 Catalym Gmbh Anti-GDF15 antibody and dosage regimen for cancer treatment
MX2023011655A (es) 2021-03-31 2023-10-11 Cambridge Entpr Ltd Inhibidores terapeuticos de la se?alizacion de gdf15.
IL310535A (en) 2021-08-10 2024-03-01 Byomass Inc Anti-gdf15 antibodies, compositions and uses thereof
WO2023122213A1 (en) 2021-12-22 2023-06-29 Byomass Inc. Targeting gdf15-gfral pathway cross-reference to related applications
CA3250445A1 (en) * 2022-01-26 2025-03-10 Yunnan Baiyao Group Co., Ltd. ANTIBODY MOLECULE DIRECTED AGAINST DIFFERENTIATION AND GROWTH FACTOR 15 AND ITS USE
CN119487065A (zh) 2022-05-09 2025-02-18 舒泰神（北京）生物制药股份有限公司 特异性识别gdf15的抗体及其应用
CN116462757A (zh) * 2023-03-24 2023-07-21 科兴生物制药股份有限公司 Gdf15的单域抗体及其应用
TW202547861A (zh) * 2024-04-23 2025-12-16 大陸商勁方醫藥科技(上海)股份有限公司 抗gdf-15抗體及其應用
CN118878677A (zh) * 2024-09-29 2024-11-01 江苏凯基生物技术股份有限公司 一种IgM亚型单克隆抗体及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
US6465181B2 (en) 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
WO2000070051A1 (en) 1999-05-17 2000-11-23 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh NEUROPROTECTIVE PROPERTIES OF GDF-15, A NOVEL MEMBER OF THE TGF-β SUPERFAMILY
US7141661B2 (en) 2000-09-08 2006-11-28 The United States Of America As Represented By The Department Of Health And Human Services Non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
DK2311873T3 (en) * 2004-01-07 2018-11-26 Novartis Vaccines & Diagnostics Inc M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF
PT2441466E (pt) * 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
CA2694863A1 (en) * 2007-08-16 2009-02-19 Garvan Institute Of Medical Research Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
KR101318549B1 (ko) 2008-09-29 2013-10-16 로슈 글리카트 아게 인간 ｉｌ17 에 대한 항체 및 이의 용도
US20120309697A1 (en) 2009-10-28 2012-12-06 Samuel Norbert Breit Methods of diagnosing and prognosing colonic polyps
US9212221B2 (en) * 2010-03-03 2015-12-15 Detroit R & D, Inc. Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
JP6013915B2 (ja) * 2010-11-17 2016-10-25 中外製薬株式会社 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN102321173B (zh) 2011-08-12 2013-04-03 中国医学科学院肿瘤研究所 人源化巨噬细胞抑制因子1单克隆抗体及其应用
EP2565262A1 (en) 2011-08-31 2013-03-06 VTU Holding GmbH Protein expression
US9714276B2 (en) 2012-01-26 2017-07-25 Amgen Inc. Growth differentiation factor 15 (GDF-15) polypeptides
CN104853775B (zh) * 2012-09-26 2023-10-20 尤利乌斯·马克西米利安维尔茨堡大学 针对生长和分化因子15(gdf-15)的单克隆抗体
MX370720B (es) 2012-12-21 2019-12-20 Aveo Pharmaceuticals Inc Anticuerpos anti-gdf15.
BR122023027559A2 (pt) 2014-03-26 2024-01-30 Julius-Maximilians-Universität Würzburg Anticorpos monoclonais para fator de crescimento e diferenciação 15 (gdf-15), estojo compreendendo os mesmos, vetor de expressão que codifica os mesmos e linhagem de célula capaz de produzir os mesmos

Also Published As

Publication number Publication date
DK3653644T5 (da) 2024-08-26
IL248038B (en) 2020-08-31
SMT202000064T1 (it) 2020-03-13
US20230382987A1 (en) 2023-11-30
EP4316596A3 (en) 2024-04-17
AU2020260440A1 (en) 2020-11-26
HRP20200034T1 (hr) 2020-03-20
DK3653644T3 (da) 2023-12-18
JP2021119138A (ja) 2021-08-12
HUE064573T2 (hu) 2024-03-28
ES2965626T3 (es) 2024-04-16
JP2017508475A (ja) 2017-03-30
IL276405A (en) 2020-09-30
RS59700B1 (sr) 2020-01-31
IL248038A0 (en) 2016-11-30
ES2763859T3 (es) 2020-06-01
CA2943694A1 (en) 2015-10-01
BR122023027559A2 (pt) 2024-01-30
PT3122775T (pt) 2019-12-26
CY1122456T1 (el) 2021-01-27
US10604565B2 (en) 2020-03-31
FI3653644T3 (fi) 2023-12-12
NZ724649A (en) 2022-07-01
KR20160139005A (ko) 2016-12-06
EP3122775A1 (en) 2017-02-01
PL3653644T3 (pl) 2024-03-04
IL276405B (en) 2021-07-29
DK3122775T3 (da) 2020-02-03
CN106536553B (zh) 2021-03-12
AU2015238264A1 (en) 2016-10-20
JP2023098966A (ja) 2023-07-11
EP4316596A2 (en) 2024-02-07
US11760795B2 (en) 2023-09-19
AU2015238264B2 (en) 2020-09-03
CN106536553A (zh) 2017-03-22
HRP20231514T1 (hr) 2024-03-01
US20170204174A1 (en) 2017-07-20
JP6865585B2 (ja) 2021-04-28
US20260008841A1 (en) 2026-01-08
BR112016022013A2 (pt) 2017-10-31
EP3653644A1 (en) 2020-05-20
HUE047398T2 (hu) 2020-04-28
JP7607498B2 (ja) 2024-12-27
PT3653644T (pt) 2023-12-19
US20200308264A1 (en) 2020-10-01
LT3122775T (lt) 2020-02-10
US20200308265A1 (en) 2020-10-01
US20180298091A1 (en) 2018-10-18
WO2015144855A1 (en) 2015-10-01
EP3653644B1 (en) 2023-11-15
LT3653644T (lt) 2024-01-25
SI3122775T1 (sl) 2020-02-28
AU2020260440B2 (en) 2024-03-21
EP3122775B1 (en) 2019-11-13
KR102520978B1 (ko) 2023-04-11
US11634482B2 (en) 2023-04-25

Similar Documents

Publication Publication Date Title
PL3122775T3 (pl) Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu
IL294982B1 (en) nk-2 cells and genetically engineered monoclonal antibodies for cancer treatment
IL272470A (en) Methods and materials for assessing and treating cancer
IL269150A (en) Compositions and methods for treating cancer
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
HUE053452T2 (hu) Anti-PD-1 és anti-LAG3 antitestek rák kezelésére
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
IL268814A (en) Compositions and methods for treatment of cancer
PL3601358T3 (pl) Przeciwciała anty-trem2 i sposoby ich wykorzystania
IL258955A (en) Compositions and methods for treatment of cancer
IL263224A (en) Methods and compositions for treating cancers
IL253462A0 (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
IL286208A (en) Humanized influenza monoclonal antibodies and methods of use thereof
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
IL271260A (en) Multi-specific antibodies and methods of making and using thereof
DK3508502T5 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3826667T3 (da) Claudin6-antistoffer og fremgangsmåder til behandling af kræft
IL271257A (en) Multi-specific antibodies and methods of making and using thereof
PL3280440T3 (pl) Humanizowane przeciwciała anty-c1s i sposoby ich zastosowania
IL269157A (en) Compositions and methods for treating cancer
IL282478A (en) Materials and methods for treating cancer
IL272147A (en) Methods and compositions for the treatment of cancer
GB2524553C (en) Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
IL256763A (en) Compositions and methods for treating cancer